VISTA是一种抑制性免疫检查点,在前列腺癌患者接受伊匹木单抗治疗后升高
在未治疗和伊匹木单抗治疗后的前列腺癌患者肿瘤中评估抑制性免疫通路,发现治疗后肿瘤巨噬细胞上PD-L1和VISTA抑制分子水平在各自独立的巨噬细胞亚群中升高,提示VISTA是伊匹木单抗治疗后前列腺癌中的另一条代偿性抑制通路。
要点
- 伊匹木单抗治疗后前列腺癌肿瘤巨噬细胞上PD-L1和VISTA水平升高。
- PD-L1和VISTA升高见于独立的巨噬细胞亚群。
- VISTA可能是伊匹木单抗治疗后的代偿性抑制通路。
核心结论
- VISTA是前列腺癌肿瘤中伊匹木单抗治疗后的另一条代偿性抑制通路。
研究设计与样本
- 来自前瞻性手术前临床试验的未治疗和伊匹木单抗治疗后的前列腺癌患者肿瘤样本。
主要发现
- 治疗后的肿瘤中,PD-L1和VISTA抑制分子水平在各自独立的巨噬细胞亚群上升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.
引用
- Gao J, Ward JF, Pettaway CA, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017. PMID: 28346412. doi:10.1038/nm.4308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。